Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07946068
PHASE1
Aleniglipron Renal Impairment Study
Sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
View on ClinicalTrials.gov
Summary
The purpose of this study is to evaluate the effect of severe RI on IHD on the PK of aleniglipron to establish scientifically guided dosing recommendations in these special patient populations.
Official title: A Phase 1, Single-Dose, Open-Label Study to Evaluate the Effect of Renal Impairment on Aleniglipron Pharmacokinetics
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
16
Start Date
2026-12
Completion Date
2027-03
Last Updated
2026-11-18
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
Aleniglipron
Administered orally
Locations (1)
Research Site
Orlando, Florida, United States